RxDoctor Payments Data

Rajnish Chawla, MD

Internal Medicine · Mercerville, NJNPI 1932197456

Payments from drug & device makers

$2,427in general payments, 2019–2025

Across 86 payments — averaging $28.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biohaven Pharmaceuticals, Inc.$1K
  • AstraZeneca$307
  • Novo Nordisk$165
  • Lilly USA, LLC$139
  • Bayer$96
  • Johnson & Johnson$56
  • plus $352 from 12 others

What the payments were for

  • Consulting fees$1,20049%
  • Travel & lodging$1125%
  • Food & beverage$1,10045%
  • Education$141%

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,427 in reported general payments places this provider in the 75th percentile of 4,032 internal medicine providers in New Jersey.

See all internal medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$79,881
Medicare patients
128
Services billed
862

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide34$75,170
OzempicSemaglutide43$52,764
JanuviaSitagliptin Phosphate44$34,326
LinzessLinaclotide28$25,912
XareltoRivaroxaban37$25,393
EliquisApixaban33$25,302
Janumet XrSitagliptin Phos/Metformin Hcl15$18,964
JardianceEmpagliflozin16$16,295
Saxagliptin-Metformin ErSaxagliptin Hcl/Metformin Hcl16$8,957
LivaloPitavastatin Calcium18$8,901
TradjentaLinagliptin14$8,849
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$7,829
Pitavastatin Calcium15$7,296
Olmesartan-Amlodipine-HctzOlmesartan/Amlodipin/Hcthiazid18$5,524
Fluticasone-SalmeterolFluticasone Propion/Salmeterol14$5,427

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$139$75,17034 claims
MerckJanuvia, Janumet Xr$36$53,28959 claims
Novo NordiskOzempic$165$52,76443 claims
Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr$49$28,52041 claims
AbbVieLinzess, Synthroid$26$28,20566 claims
Johnson & JohnsonXarelto$56$25,39337 claims
PfizerEliquis$15$25,30233 claims
Kowa Pharmaceuticals America, Inc.Livalo$55$8,90118 claims
GSKTrelegy Ellipta$39$7,82912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,032 internal medicine providers in New Jersey.

Other internal medicine in Mercerville

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →